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Non-prescribed Anabolic-Androgenic Steroid (AAS) use has increased during recent 
years. Often used “recreationally” and for aesthetic purposes, AAS are easily purchased 
over the internet and informally from gym-using peers. Social workers have a 
responsibility to support service users, to identify and manage risks and AAS use raises 
some noteworthy challenges to social work practice. This literature review aims to 
identify AAS-related knowledge social workers might require and consider its 
implications for social work practice. Although some of the evidence is inconclusive, 
particularly in relation to causal relationships between AAS use and behavioural 
change or polysubstance use implications, there are consequences that could cause 
significant short and long-term harm to physical and/or psychological health to young 
people. Social workers should consider the possibility that a young person may be 
vulnerable to using AAS without being fully aware of the risks, as this could result in 
harm reduction and enhanced outcomes among this easily overlooked population. While 
rarely addressed in the existing social work literature, the risks associated with AAS 
usage, particularly in young people, necessitate more awareness and attention from 
social work practitioners particularly in today’s image conscious society.  
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Title: Social work implications of anabolic-androgenic steroid (AAS) use, particularly among 
young people: A review of the literature 
Introduction  
Anabolic-androgenic Steroids (AAS) are those drugs that relate to testosterone and its synthetic 
derivatives and are increasingly used recreationally by the general population for their anabolic effects 
to build muscle mass (McVeigh and Begley 2016).   As an array of evidence pertaining to the 
detrimental physical and behavioural consequences of AAS use has emerged since 2000 (Evans-
Brown et al. 2012), it appears timely to consider the need for professionals to have an understanding 
of AAS use as wider engagement with stakeholders, including social workers, around the issues of 
using AAS could help to minimise harm (Evans-Brown et al. 2012).   A global lifetime prevalence of 
AAS is indicated at 3.3% (men: 6.4%, women: 1.6%) (Sagoe et al. 2014) and users often take 
supraphysiological doses orally or via injection (Pope Jr. and Kanayama 2012). Whilst users still 
represent a minority of the overall substance using population in the UK, the National Crime Survey 
(NCS) estimated that just under 61,000 16-59 year-olds had used AAS in 2017/2018; 17000 of these 
were 16-24yr-olds (UK Home Office 2018), which is an increase on previous years. This could be an 
under-estimate, as the NCS relies upon self-reported data. The Advisory Council on the Misuse of 
Drugs (2010) expressed particular concerns for the potential negative impact of AAS use on the 
physiological and behavioural development of young people.  This increase in recreational use also 
raises practice implications when working with young people, especially those who may be 
susceptible to body image concerns as studies have highlighted both the negative impact of social 
media on body image for young people (de Vries et al. 2016) and found high concerns around 
muscularity are common in adolescent boys (Field et al. 2014) . 
 
Social work, risk and substance use  
To be effective and meet the challenges of evidence-based practice (EBP), social workers require an 
extensive, relevant and identifiable knowledge base (Thompson 2005). An examination of current 
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standard social work and substance use textbooks suggests that general information for social workers 
remains scarce; e.g. Paylor, Wilson and Measham (2012) refer to AAS use once and there is a short 
synopsis in Heanue and Lawton (2012) but no information is found in Goodman (2013) or Parrish 
(2014). Moreover, studies have shown that often social workers lack confidence in working with 
substance abuse and this has been recognised as a shortfall in social work education (Galvani and 
Forrester 2011). While not all social workers subscribe to the British Association of Social Workers 
(BASW) Code of Ethics, the BASW Policy Ethics and Human Rights Committee (2012, p12) 
nonetheless provides a relevant set of guidelines for professional practice, including the obligation to 
help people “to identify and manage potential and actual risk”.  Galvani (2015) suggests the need for 
practitioners to fulfil three roles entailing specific capabilities aligned to working with harmful 
substance use to:  
• Engage with the topic to support service users,  
• Motivate people to consider changing their behaviours, 
• Support people in maintaining changes.  
In keeping with Galvani’s perspective, the authors have sought to incorporate her suggestions into the 
consideration of practice implications. Consequently, to identify areas for enhanced practice, the 
findings and discussion will focus on the first two of Galvani’s (2015) aforementioned roles. 
Aims 
The aims of this review are to:  
• Provide an overview of the physical and psychological harms associated with AAS use, 
• Identify the motivations for recreational/non-prescribed AAS use, 
• Identify the risks of AAS use to young people (adolescents: age 13-19), 
• Explore the implications for social workers working with those at risk of AAS use. 
For the purposes of brevity, the phrase ‘AAS users’ will be used to refer to people who choose to use 
AAS.  
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Methods  
To explore the nature and scope of the problem, the authors have undertaken a literature review, as 
such a review supports EBP (Aveyard 2014). This review covers material published primarily 
between January 2007 and July 2017, however when no information was found on relevant areas (for 
example domestic and child sexual abuse) within these date restrictions, the restrictions were 
broadened (1990 - 2017) to include pertinent articles. 
 
Identification and Selection of Studies  
The literature was searched following a systematic process and included peer-reviewed publications, 
case studies and Government reports. To select the most relevant literature, searches of terms such as 
‘anabolic-androgenic steroids’, ‘image and performance enhancing drugs’ and associated acronyms 
were combined with the term ‘social work’ in the EBSCOhost online database. When no specific 
results were found, the search was widened to include terms for areas of risk e.g. safeguarding, 
violence, mental health. A complete list of search terms is at Appendix 1.  
Specific inclusion (e.g. peer-reviewed literature) and exclusion criteria (e.g. excluding animal studies, 
prescribed steroids) were applied to ensure the most relevant articles were included. Where it was not 
possible to refine the results using inclusion and exclusion criteria, titles and/or abstracts were used to 
determine whether sources should be included based on the relevance to the research question. As the 
majority of AAS users are male due to the motivation to increase muscle size (Kanayama et al., 2009) 
and the majority of studies are focussed on male populations, this review concentrates on the risks for 
male AAS users. 
Studies chosen were selected because of their potential contribution to the subject in relation to social 
work, which could have led to potential selection bias. Another possible limitation is that useful 
evidence may have been omitted as only English language articles were included; specific exclusion 
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criteria were used and the limitations of the databases searched. Other considerations for omissions 
could be the lack of consistent terminology around IPED use.  
 
 
Risks of physical harm of Anabolic-androgenic Steroid use  
Physical harm from using AAS can include acne, erectile dysfunction, hypogonadism, headaches, 
heart palpitations, testicular atrophy, liver toxicity, renal failure, dermal scarring, memory loss and 
cognitive problems, raised blood pressure, gynaecomastia (breast enlargement), muscle damage, 
myocardial injuries, and infertility (Nieschlag and Vorona 2015). Of the potentially negative physical 
side effects of AAS, only some are reversible after cessation (van Amsterdam, Opperhuizen, and 
Hartgens 2010). Furthermore, exposure during adolescence alters the normal pattern of brain 
development as well as neurotransmitter function and adult behaviour patterns (Cunningham, Lumia, 
and McGinnis 2013). There have been cases of prolonged AAS-use related deaths, however 
specifying their role is sometimes made difficult, as a cocktail of drugs is often involved (Frati et al. 
2015). There is also a risk of harm due to the quality of the drugs, as the AAS sold may be of variable 
strength, adulterated, or counterfeit (Cho et al. 2015). A study of websites on AAS use found that less 
than 5% of those websites presented reliable health information (Clement et al. 2012); which is 
particularly concerning as studies have found that many AAS users seek out information on AAS use 
from websites and online forums (Harvey et al. 2019). An awareness of the physical harms could help 
social workers credibly discuss the risks with users and support them to revaluate their use or seek 
professional support from specialist AAS services, their GP or counselling services.  
 
Behavioural and psychological impact of using Anabolic-androgenic Steroids  
AAS users report increased libido during AAS use (Petersson et al. 2010), are more likely to engage 
in high-risk sexual behaviours, and have more multiple partners than the general population (Ip et al. 
2016; R. Brennan, Wells, and Van Hout 2017). However, the increase in libido does not last, and 
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reduces significantly when use ceases (Petersson et al. 2010). This increased libido, if acted upon, 
could suggest AAS users may be at more risk of contracting blood borne viruses (BBVs) or sexually 
transmitted infections and subsequently pass these on to partners. AAS users also face risks of 
contracting BBVs and HIV due to risky injecting practices and sharing vials (R. Brennan, Wells, and 
Van Hout 2017; Ip et al. 2016). Yet, the authors of both papers agree that this risk was lower than 
traditional intravenous substance users. Studies show that about 30% of AAS users use doctors or 
Needle Exchanges to access tests for Hepatitis B and C (Hope et al. 2015; Zahnow et al. 2017). 
However, 30% is not a high number of users, and the majority of participants in these studies were not 
adolescents. Young initiates to AAS use are thus potentially at heightened risk of BBVs and other 
infections unless they are encouraged to use safe injection practices and contraception.  
 
The psychological effects of AAS use depend upon a range of factors such as type and dose of AAS, 
effects of use in combinations, pre-existing conditions and personality (Barceloux and Palmer 2013). 
Common effects include anxiety, mood disturbances and reckless behaviour (Piacentino et al. 2015). 
Links have been found between cessation of AAS use and depression, and AAS dependent users were 
more likely to report diagnoses of anxiety or major depressive disorder than non-dependent AAS 
users (Ip et al. 2012; Kaufman et al. 2015). While AAS use may be linked with mental health 
problems, the impact on individuals is idiosyncratic and unpredictable (Kanayama, Hudson, et al. 
2010) therefore social workers should be alert for mental health-related problems, regardless of 
whether AAS is the cause of the mood disturbances or being used to alleviate them. 
 
Unlike animal studies which link testosterone and aggression, the relationship between AAS and 
aggression in humans is inconclusive (Tomlinson, Brown, and Hoaken 2016). Yet, a UK study of 638 
Image and Performance Enhancing Drugs (IPED) users found that 110 participants reported increased 
aggression and 164 reported mood swings (Bates and McVeigh 2016) and Piacentino et al.’s (2015) 
review linked long-term AAS use with the potential for increased aggression, mood destabilisation 
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and psychoses. Three relatively large studies found adolescent AAS users reported significantly 
increased levels of aggression compared to non-users (Beaver et al. 2008; Kokkevi et al. 2008; 
Jenssen and Johannessen 2015). Adolescent AAS use is linked with heightened vigilance in response 
to social encounters (Cunningham, Lumia, and McGinnis 2013) and there is a significant relationship 
between aggression and adolescent exposure to AAS use (Sagoe, Andreassen, et al. 2015). 
Adolescents who scored high on tests for aggression were more likely to report intent and curiosity 
towards initiating AAS use (Sagoe et al. 2016). Adult AAS users who started using before age 
nineteen reported more impulsivity and behavioural disinhibition, and poorer planning and affective 
processing while using (Hildebrandt et al. 2014). The authors found that early onset use was 
associated with more hostility, but not other types of aggression when compared with users who 
started using after the age of twenty-two. The prevalence of antisocial behaviours including the 
bullying of peers was highest amongst AAS users when compared to non-AAS users (Hallgren et al. 
2015). This study also noted a higher proportion of AAS users engaged in criminal activities such as 
theft, using weapons and rape. AAS use has been used in preparation for crime (Klötz et al. 2007), 
notably the case of Anders Breivik who used AAS in preparation for the July 2013 atrocities and as an 
adolescent (Melle 2013). Breivik provided details of his steroid use in his manifesto and primer for his 
followers (Breivik 2011). This is not to suggest that young people who choose to use AAS are 
involved in such activities, but is an example of the internet providing a place where potentially 
vulnerable young people can access information that could potentially put them at risk. 
 
Regardless of whether AAS use increases the risk of aggression or if it is an indicator of low threshold 
for aggression, others could be put at risk. Skårberg, Nyberg, and Engström’s (2008) qualitative study 
found that three of the five male AAS-users reported pathological jealously which caused relationship 
difficulties. AAS users reported more incidents of having assaulted/threatened female partners 
(Skårberg and Engstrom 2007) and a study of 23 AAS users and 14 nonusers found AAS users 
reported more incidents of aggression against significant others than not when on AAS (Choi and 
Pope Jr. 1994). This could suggest that partners of AAS users may be more at risk of experiencing 
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violence when the AAS users are taking AAS. Assessing the links to aggression is complicated by the 
potential causal factors such as social background, polysubstance use and that the majority of studies 
rely on self-reported information. Moreover, the authors could find no studies that specifically sought 
information from partners and those close to people who use steroids about the impact on behaviour 
that they saw resulting from AAS use.  
 
Adolescent AAS users might be parents or might be living in homes where young children are present 
therefore, consideration needs to be given to the potential risks to children. One case study suggested 
a link between AAS use and child sexual abuse; the participant reported having increased sexual 
desires as a result of the AAS use and whilst taking AAS had a male child masturbate him (Driessen 
et al. 1996). However, the authors found no further evidence in the literature to correlate AAS use and 
child sexual abuse. The evidence to suggest that children are at risk from harm from AAS users is 
limited, however it should not be ruled out completely. Social workers might find it prudent to alert 
AAS users and their families about the possible behavioural changes that could lead to more 
aggressive behaviour and also the potential risk of children accidentally consuming illicit substances, 
as illicit AAS does not come in child-resistant packaging (Evans-Brown et al. 2012). 
 
Polypharmacy and use of Anabolic-androgenic Steroids  
  
Two reviews exploring the links between AAS use and polypharmacy found a positive association 
between the use of alcohol, illicit substances and AAS (Dodge and Hoagland 2011; Sagoe, McVeigh, 
et al. 2015), but gave no clear conclusions as to the relationships around causality and prevalence. 
Polysubstance use complicates any consideration of the impact of AAS on mental health. AAS users 
may use additional substances to achieve their goals or to alleviate AAS side effects e.g. taking 
amphetamines to train more; benzodiazepines to sleep or reduce pain (Skårberg, Nyberg, and 
Engström 2008). The authors hypothesised that AAS use could be a potential gateway substance as 
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the five male AAS users reported starting on AAS before adding other substances. However, in a 
study of individuals suspected of infringing Swedish narcotics laws 55% of their subjects’ narcotics 
use preceded their AAS use (Gårevik and Rane 2010). Polysubstance use with AAS use was 
significantly correlated with violent crime (Lundholm et al. 2015) and also with aggressive 
behaviours (van Amsterdam, Opperhuizen, and Hartgens 2010). 
 
In assessing risk around substance use, people diagnosed with substance dependence could be 
considered at greatest risk of harm and substance dependence consistently raises questions of masking 
other underlying problems (Rudd 2014). The ICD-10 (World Health Organisation 2010) lists AAS as 
non-dependence producing substances whereas the DSM-5 (APA 2013) categorises AAS under 
“other” substances but does not explicitly state non-dependent and instead has criteria for substance 
use disorders (e.g., mild anabolic steroid use disorder). One study found substantial evidence for AAS 
dependence and a 30% likely prevalence amongst AAS users (Grönbladh, Nylander, and Hallberg 
2016). Kanayama et al. (2010) proposed three pathways for developing dependence:  
• Body image (fear of losing muscle size);  
• Androgenic effects (loss of sexual function, fatigue, depression); 
• Hedonic effects (reinforced psychoactive effects such as increased confidence and 
aggressiveness).  
Although there is evidence for the possibility of developing AAS dependency, there is a lack of clarity 
around determining specific risk factors for dependency. Social workers need to be aware that AAS 
use varies from stereotypical substance dependency, in that the substances themselves may not cause 
physical dependence per se, but there may be psychological elements for the dependence e.g. positive 
feelings and peer admiration linked to increased muscle size (Griffiths et al. 2016).  While these 
factors may not be sufficient to meet the criteria for dependence, professional awareness of 
progressive usage patterns may prove relevant to identifying vulnerability, and matching needs with 
the support available. 
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Motivations for using Anabolic-androgenic Steroids  
Understanding the motivations for using substances is essential to effective professional practice with 
people misusing substances (Galvani 2015). The most prominent motivations for AAS use are 
enhanced physical appearance and/or improved physical performance, a full list of motivations is 
summarised in Table 1. 
 
Table 1. Further motivations for use 
 
As improving appearance and enhancing performance are prominent motivators for AAS use, this 
raises the question: what is driving this desire? The DSM-5 (APA 2013) links AAS use with some 
cases of muscle dysmorphia (MD), a form of body image disturbance and notes that MD occurs 
predominantly in men, affecting those with “normal” physiques who are preoccupied with the idea 
that their body is not sufficiently muscular. AAS users who self-reported using AAS to improve their 
appearance had greater overall disordered eating and MD symptomatology (Murray et al. 2016). AAS 
users had a similar prevalence of psychiatric symptomatology, e.g. anxiety, depression, interpersonal 
sensitivity and obsessive-compulsive behaviour as men with eating disorders, but did not share the 
same negative self-image (Björk, Skårberg, and Engström 2013). Potentially, seeing their muscles 
develop as a result of exercise and AAS use had helped them overcome previous negative self-
images. Over- and underweight boys were four times more likely to use AAS than boys who 
perceived themselves as the right weight (Jampel et al. 2016). Looking at initial and current 
motivations for use, Harris, Dunn, and Alwyn (2016) found that the initial external motivation of 
wanting to be more muscular led to an internal motivation of body image concerns. The authors 
concluded that continued AAS use could be linked to the development of body image disorders 
among young people.  
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Adolescent concerns about muscles and body image and body checking behaviour are predictive 
factors for AAS use (Jenssen and Johannessen 2015), as are participation in sports, and diagnosed 
depression (Sagoe, Andreassen, and Pallesen 2014). AAS is normally used in conjunction with an 
exercise regime (Hakansson et al. 2012); users tend to exercise more than non-users (Onakomaiya and 
Henderson 2016) and students who exercised daily increased the odds of lifetime AAS use (Kokkevi 
et al. 2008). Other factors that potentially predict AAS use in adolescents are the use of legal-
performance-enhancing substances e.g. protein supplements, and ease of access to AAS via the 
internet (Karazsia, Crowther, and Galioto 2013; B. Brennan, Kanayama, and Pope Jr. 2013). Social 
workers who are curious to know if a young person is engaged in AAS use, could talk with them 
about physical activity, healthy eating and body image. Terms such as ‘shredded’ to describe an ideal 
body are used by AAS users (Underwood 2017), so an adolescent’s use of such terms could indicate 
an interest in building muscle, and other possible signs could be use of protein supplements or 
membership of online bodybuilding forums or Instagram feeds. 
 
One study of 518 AAS users highlighted that 90% of participants planned to continue their usage 
despite negative side effects (Ip et al. 2011), and over 50% of AAS users thought AAS were not 
harmful to their health if used correctly (Alsaeed and Alabkal 2015). AAS users did not generally 
express anxiety over the harms of using and viewed their new lifestyle as having alleviated previous 
problems such as obesity and depression (Kimergård 2015). R. Brennan, Wells, and Van Hout (R. 
Brennan, Wells, and Van Hout 2017) suggest that high-risks may be normalised within IPED 
communities and that AAS users may “disassociate from potential harms”. This information is 
relevant to social work as denial and rationalisation can be resistant to change (Harmon-Jones 1999), 
potentially compromising the service user’s motivations to stop AAS usage.  
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In a large US study of adolescent males, respondents perceived AAS use as less risky or harmful 
when they considered it easily obtained, if they had close friends who used AAS, or if they self-
reported low levels of self-esteem, depression or risk-taking behaviours (Denham 2009). AAS users 
only sought treatment when the negative experiences outweighed the positive experiences (Skårberg, 
Nyberg, and Engström 2008), and tend to seek out advice from anonymous sources or personal 
networks (Larance et al. 2008). They often rely on ‘bro-science’ (information from other AAS users) 
(Underwood 2017; Hanley Santos and Coomber 2017) for information on combining drugs and risks; 
question the harms noted by medical professionals and prioritise information from experienced AAS 
users (Kimergård 2015). A potential risk for adolescents wishing to enhance their body to meet 
stereotypical masculine norms is the seeking out of role models who have enhanced their own body 
image and being unduly influenced by them. Social workers should be mindful that their expertise 
may be perceived as inferior to the peer group’s advice.  
 
There have been a range of noteworthy psychosocial influences on the initiation of AAS use 
including: family histories of divorce, poor social support, childhood and adolescent conduct 
disorders, history of mental or physical abuse, problems at school, time in foster care and problematic 
parental interactions (Sagoe, Andreassen, and Pallesen 2014; Pope Jr., Kanayama, and Hudson 2012; 
Skårberg and Engstrom 2007; McDonald et al. 2014). One study found a negative relationship with 
fathers linked to AAS use, but identified no correlation with child sexual abuse or a reported family 
history of substance dependence  (Pope Jr., Kanayama, and Hudson 2012); however, an earlier study 
had found that AAS users were more likely than non-users to have a history of sexual abuse (Ip et al. 
2011). 
 
Knowledge and skills for social workers 
This review has identified risks to young people who use AAS. Parrish (p187, 2014) highlights the 
need for social workers to be aware of the implications in the area of substance use “regardless of 
13 
 
their identified area of expertise”.  For example, social workers may well encounter AAS-related 
concerns among young people whose Adverse Childhood Experiences place them at risk of body 
image concerns or looked after children who lack positive male role models.  Because of social 
work’s inherent person-in-environment emphasis they are amongst the helping professions most likely 
to understand dominant social and cultural scripts such as masculinity (Shafer and Bellamy 2016), 
peer group influences and social media pressure. Social workers need to establish sufficient rapport 
and trust to ask about substance use in order to encourage disclosure and offer support (Galvani, 
Hutchinson, and Dance 2014).  Asking AAS users their own reasons for using AAS, while avoiding 
implications of stigma or disapproval aligns to taking a person-centred approach (Petersson et al. 
2010), which is anti-oppressive and empowering (Thompson 2005).  
Approaching young people’s AAS use with an appreciation of the benefits of use may enhance 
professional credibility with young AAS users (Griffiths et al. 2016). Professionals need to understand 
the physical (the increase in muscle size and strength gain) and psychological (positive reinforcement 
from attaining desired results) benefits as well as the associated side effects and harms from use. 
Understanding that a person’s perception of their body and their perception of gender norms may be 
possible motivations for using AAS, and that initiating AAS use could lead to young people and men 
developing unrealistic norms around body image (Harris, Dunn, and Alwyn 2016) allows 
professionals to be better placed to assess risks to young people. Moreover, identifying someone’s 
motivations for use could help ensure that they are signposted to the right type of support, e.g. support 
for adverse side effects or psychological support to address an underlying issue. Social workers are 
strongly placed to incorporate such practice frameworks as Prochaska and DiClemente’s (Prochaska 
and Diclemente 1986) Cycle of Change and motivational interviewing (Miller and Rollnick 2013). 
Social workers are further advantaged by their professional emphasis on a psychosocial perspective 
informing practice (Parrish 2014). 
 
People can make unwise decisions and professionals must consider the possibility that users may 
focus on the benefits for a variety of reasons including but not exclusively: peer pressure, lacking 
14 
 
sufficient information, having a poor understanding in relation to harm, perceiving risks to outweigh 
benefits, or being more vulnerable due to pre-existing mental health difficulties. In terms of providing 
the best possible outcomes for adolescents, it could be beneficial to support a young person accessing 
the gym to help their overall physical wellbeing. However, giving consideration to the potential 
susceptibility of vulnerable adolescents to AAS use, effective discussions with them regarding the 
risks that could come from this type of environment are crucial, especially as adolescence is a 
developmental stage, when risk-taking behaviours are more prevalent than in child or adult-hood 
(Slee, Campbell, and Spears 2012).  Furthermore, it is beneficial to educate parents about AAS use in 
order to help influence and support adolescent users (Dodge and Clarke 2015). This is especially 
relevant as the prevalence of fake AAS and reliance of information from the internet suggests 
practitioners need to be aware that websites tend to be biased towards pro-AAS use whilst 
downplaying the risks (Clement et al. 2012). 
 
Social workers should also be aware of the legal status of AAS use within their own country as legal 
factors further complicate steroid use. Possession of AAS for personal use in the UK is legal (Misuse 
of Drugs Act, 2017), supplying and on-line purchasing of steroids remain illegal which is similar to 
Canada. Simultaneously, purchasing steroids in other countries in which they are legal, and bringing 
them back into the UK remains legal. However, in countries such as the US non-prescribed steroid 
use is illegal whereas use is legal in other parts of the world e.g. Hong Kong. Such factors make the 
law around purchase and supply complex and this could link to under reporting, secrecy around 
personal use and reluctance to access support. 
 
When working with AAS users, a non-judgemental approach is needed by professionals (R. Brennan, 
Wells, and Van Hout 2017) which includes the need for careful listening to understand their 
experiences and not relying on assumptions based on stereotypes (Skårberg, Nyberg, and Engström 
2008). One way to do this could be by reflecting on their own beliefs about AAS use, as it is 
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important for professionals to reflect on their own values around substance use (Galvani, Hutchinson, 
and Dance 2014). This is particularly important as many AAS users cite that a barrier to accessing 
support is the judgement that they perceive they will receive from professionals (Yu, Hildebrandt, and 
Lanzieri 2015). AAS users believe that the public has a distorted view of the negative side-effects of 
use (Cohen et al. 2007) and when considering AAS in society, often the media portrayal plays a key 
role. AAS users feel stigmatised by the public and press e.g. media depictions often focus on stories 
of ‘roid rage’ (Griffiths, Murray, and Mond 2016). This was evidenced recently in the wide-spread 
coverage of how the Westminster and London Bridge attacks that the perpetrators were reported to 
have used steroids prior to the attacks (Hamilton 2018; Weaver 2018), yet the subsequent inquest into 
the Westminster attack concluded that steroids were unlikely to have caused behavioural changes 
(Telegraph Reporters). As such, it is incumbent upon social workers to be aware of these risks but not 
to fall prey to the widely-held public belief that it causes ‘roid rage’ in all users as risk assessments 
need to be balanced. 
 
Limitations and recommendations for future research 
When considering the conclusions of this review, it is useful to highlight possible limitations and the 
scope of this review was ambitious and so this is reflected in the limited depth in some areas and use 
of recent literature reviews. There are limitations as non-prescribed AAS are potentially used in a sub-
cultural environment that confounds ascertaining accurate estimates of users (Skårberg, Nyberg, and 
Engström 2008) and individuals may be unwilling to participate in studies. Many of the studies were 
based on small sample sizes of AAS users, the larger size studies were often from cross-sectional 
studies that did not necessarily set out to measure the AAS use and its effects and the type of user was 
not clearly defined. In many of the studies, ethnicity was categorised as white, although there are 
studies that show that people from a range of ethnic backgrounds use AAS (van Hout and Kean 2015; 
Bates and McVeigh 2016). When using surveys and questionnaires, studies can be affected by self-
reporting biases (Sheppard 2004) as often the extent of the AAS use and effects of the use were reliant 
16 
 
on the participant’s recall and honesty. The lack of data on the potential risks faced by partners and 
families of AAS users highlights this as a much needed area for future research.  
 
Conclusion 
Some of the evidence is not conclusive, particularly in relation to causal relationships between AAS 
use and behavioural change or polysubstance use, and not all adolescent AAS users will experience 
these risks, there are significant physical and psychological risks to self in relation to use which may 
be compounded by combining AAS with other illicit substances. Vulnerable people who could be 
more at risk of starting to use could be adolescents with poor self-image, adverse childhood 
experiences, or conduct problems. Given people’s right to make unwise decisions under the Mental 
Capacity Act (HM Government, 2005) professionals could argue that there is no need for direct 
involvement unless the young person is actively seeking support. However, giving consideration to 
the possibility that a young person may be vulnerable to starting to use AAS or might be using AAS 
without being fully aware of the risks that they are taking could result in harm reduction and enhanced 
outcomes among this easily overlooked population. Considerably more research is needed regarding 
psychosocial factors related to young people at risk of AAS use.   
In conclusion, an awareness of the risks associated with AAS use is both relevant and important 
knowledge for social work practice with an array of services users. The social work roles identified by 
Galvani (2015) are clearly applicable when it comes to working with young people who use AAS 
across a spectrum of settings.  Developing expertise related to the complexities of AAS use is clearly 
needed to establish credibility and confidence among social workers.  Social work education and 
training provides readily transferrable skills that are highly relevant to engaging with service users in 
ways that are trustworthy, credible and non-judgemental, providing motivation, and supporting 
change. Thus the authors argue that the existing literature serves to emphasise the relevance of sound 
social work practice in the burgeoning need for professional expertise in relation to AAS usage. 
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